The status of p53 in the metastatic progression of colorectal cancer

European Journal of Cancer Part A

Volumn 33, Issue 8, 1997, Pages 1314-1322

  Heide, I ^a   Thiede, C ^a,c   Sonntag, T ^a   De Kant, E ^a   Neubauer, A ^a   Jonas, S ^a   Peter, F J ^a   Neuhaus, P ^a   Herrmann, R ^b   Huhn, D ^a   Rochlitz, C F ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Colorectal cancer metastase; Immunohistochemistry; Loss of heterozygosity; mRNA expression; p53 mutations; PCR

Indexed keywords

MESSENGER RNA; PROTEIN P53;

ARTICLE; CLINICAL PROTOCOL; COLORECTAL CANCER; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 17144473545     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00118-4     Document Type: Article

References (56)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253, 49-53.
2. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991, 351, 453-456.
3. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990, 250, 1233-1238.
4. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990, 348, 747-749.
5. Malkin D, Jolly KW, Barbier N, et al. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J med 1992, 326, 1309-1315.
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54, 4855-4878.
7. Soussi T, Caron-de-Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990, 5, 945-952.
8. Hartmann A, Blaszyk H, McGovern RM, et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 1995, 10, 681-688.
9. Milner J, Medcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991, 65, 765-774.
10. Cox LS, Lane DP. Tumor suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays 1995, 17, 501-508.
11. Bischoff JR, Friedman PN, Marsjak DR, Prives C, Beach D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proc Natl Acad Sci USA 1990, 87, 4766-4770.
12. Milner J, Cook A, Mason J. p53 is associated with p34cdc2 in transformed cells. Embo J 1990, 9, 2885-2889.
13. Shaulsky G, Goldfinger N, Tosky MS, Levine AJ, Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene 1991, 6, 2055-2065.
14. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992, 71, 587-597.
15. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992, 70, 923-935.
16. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992, 70, 937-948.
17. Lane DP. Cancer. p53, guardian of the genome. Nature 1992, 358, 15-16.
18. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature 1992, 358, 83-86.
19. Kern SE, Kinzler KW, Baker SJ, et al. Mutant p53 proteins bind DNA abnormally in vitro. Oncogene 1991, 6, 131-136.
20. Unger T, Nau MM, Segal S, Minna JD. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. Embol J 1992, 11, 1383-1390.
21. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990, 50, 7717-7722.
22. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994, 106, 42-48.
23. Hamelin R, Goh HS, Chan CS, Khine K, Smith DR. p53 and behaviour of colorectal cancer. Lancet 1994, 344, 233-234.
24. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995, 55, 5217-5221.
25. Smith DR, Ji CY, Goh HS. Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas. Br J Cancer 1996, 74, 216-223.
26. Zeng ZS, Sarkis AS, Zhang ZF, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994, 12, 2043-2050.
27. Auviven A, Isola J, Visakorpi T, Koivula T, Virtanen S, Hakama M. Overexpression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994, 70, 293-296.
28. Mulder JW, Baas IO, Polak MM, Goodman SM, Offerhaus GJ. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer 1995, 71, 1257-1262.
29. Heide, I, Thiede C, Poppe K, de Kant E, Huhn D, Rochlitz C. Expression and mutational analysis of Nm23-H1 in liver metastases of colorectal cancer. Br J Cancer 1994, 70, 1267-1271.
30. Horn GT, Richards B, Klinger KW. Amplification of a highly polymorphic VNTR segment by the polymerase chain reaction. Nucleic Acids Res 1989, 17, 2140.
31. Banks L, Matlashewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986, 159, 529-534.
32. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984, 32, 219-229.
33. Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 1989, 4, 1153-1157.
34. Neubauer A, Neubauer N, Liu E. Polymerase chain reaction based assay to detect allelic loss in human DNA: loss of β-interferon gene in chronic myelogenous leukemia. Nucleic Acids Res 1990, 18, 993-998.
35. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988, 70, 245-252.
36. Gussow D, Rein R, Ginjaar I, et al. The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol 1987, 139, 3132-3138.
37. O'Bryan JP, Frye RA, Cogswell PC, et al. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991, 11, 5016-5031.
38. Rideout WM, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 1990, 249, 1288-1290.
39. Tornaletti S, Pfeifer GP. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 1995, 10, 1493-1499.
40. Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' mutant phenotypes. Cell Growth Differ 1990, 1, 571-580.
41. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992, 7, 743-749.
42. de-Kant E, Rochlitz CF, Herrmann R. Gene expression analysis by a competitive and differential PCR with antisense competitors. Biotechniques 1994, 17, 934-942.
43. Shaw P, Tardy S, Benito E, Obrador A, Costa J. Occurrence of Ki-ras and p53 mutations in primary colorectal tumors. Oncogene 1991, 6, 2121-2128.
44. Bosari S, Viale G, Roncalli M, et al. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 1995, 147, 790-798.
45. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: a late event? Oncogene 1991, 6, 1685-1690.
46. Effert PJ, Neubauer A, Walther PJ, Liu ET. Alterations of the p53 gene are associated with the progression a human prostate carcinoma. J Urol 1992, 147, 789-793.
47. Kastrinakis VW, Ramchurren N, Rieger KM, et al. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogens 1995, 11, 647-652.
48. Crook T, Vousden KH. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. Embo J 1992, 11, 3935-3940.
49. Pollock RE, Lang A, Luo J, El-Naggar AK, Yu D. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 1996, 12, 2035-2039.
50. Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991, 6, 1699-1703.
51. Cunningham J, Lust JA, Schaid DJ, et al. Expression of p53 and 17p allelic loss in colorectal carcnoma. Cancer Res 1992, 52, 1974-1980.
52. Bertorelle R, Esposito G, Del-Mistro A, et al. Association of p53 gene and protein alterations with metastases in colorectal cancer. Am J Surg Pathol 1995, 19, 463-471.
53. Rochlitz CF, Heide I, Thiede C, Herrmann R, de Kant E. Evidence for a mutual regulation of p53 and c-myc expression in human colorectal cancer metastases. Ann Oncol 1995, 10, 981-986.
54. Hamelin R, Jego N, Laurent-Puig P, Vidaud M, Thomas G. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. Oncogene 1993, 8, 2213-2220.
55. Ishioka C, Suzuki T, Kanamaru R. Mutations of p53 gene in human colorectal tumor in Japan: molecular epidemiological aspects. Tohoku J Exp Med 1992, 167, 243-245.
56. Kikuchi-Yanoshita R, Konishi M, Ito S, et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 1992, 52, 3965-3971.